Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657293 | 0.82 | TAAR1 (0.64) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL7552818 | 0.80 | TAAR1 (0.61) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL96238 | 0.79 | TAAR1 (0.54) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL2096666 | 0.78 | SRD5A2 (0.59) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL934227 | 0.78 | TAAR1 (0.73) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL18856960 | 0.77 | TAAR1 (0.57) | TAAR1IDO1MAOBMIF | |
| SCHEMBL63468 | 0.76 | ALDH1A1 (0.67) | TAAR1IDO1ALDH1A1KIF11TSHR | |
| SCHEMBL649682 | 0.76 | ALDH1A1 (0.37) | IDO1ALDH1A1TSHR | |
| SCHEMBL28701927 | 0.76 | TAAR1 (0.56) | TAAR1IDO1MAOBALDH1A1KDM4E | |
| SCHEMBL10544537 | 0.76 | TAAR1 (0.56) | TAAR1IDO1MAOBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108090-A1 | METHODS OF TREATING INFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215377-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215378-A1 | METHODS OF TREATING FIBROSIS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023163971-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | ATHIRA PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230189636-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-06-15 | — | — | US | disclosed |
| EP-3717475-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-115715334-A | Growth inhibitor for forming mask-protecting film, method for forming mask-protecting film using the same, and mask produced thereby | 秀博瑞殷株式公社 | 2023-02-24 | — | — | CN | disclosed |
| CN-113149971-B | 8- (indoletriazole) substituted coumarin compound and preparation method and application thereof | 港科鹏禾生物(苏州)有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2016184378-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE AND PREPARATION METHOD AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2016-11-24 | — | — | WO | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| WO-2015085935-A1 | PYRAZOLYL PYRIMIDINAMINE COMPOUND AND APPLICATION THEREOF | 中国中化股份有限公司 | 2015-06-18 | — | — | WO | disclosed |
| WO-2014098098-A1 | HETEROCYCLIC AMIDE DERIVATIVE, AND MEDICINE CONTAINING SAME | 味の素株式会社 (JP) | 2014-06-26 | — | — | WO | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7368478-B2 | Methods for inhibiting angiogenesis and tumor growth | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2007047177-A1 | ACYL INDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| CN-1343219-A | Substituted phenethylamine derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-04-03 | — | — | CN | disclosed |
| EP-1149843-A1 | SUBSTITUTED PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230189636-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | EMC1, EMC2, EPCAM | TAAR1 3961/4885IDO1 4339/4885MAOB 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.